StableBody Technologies (SBT) introduces a next generation anti-CD45 reagent product line.
Platform production of clinically relevant reagents such as monoclonal antibodies (Mab’s) and antibody-like proteins such as single-chain antibody fragments (scFv’s) can require years of intensive laboratory and investment resources!
StableBody Technologies, LLC (SBT) has developed the BioDesign System (BDS™), a unique, state-of-the-art bioinformatic process for accelerating and achieving superior performance composition in antibody engineering.
positively impacts commercial value of scFvs by improving product success and reducing product development time.
When compared to monoclonal antibodies used in clinical applications, SBT scFvs offer:
Longer shelf life, elevated working
temperatures, and eliminated
cold chain storage & distribution
Increased sensitivity and increased specificity
Reduced costs due to shorter development times, reduced time to market, and reduced reagent usage
The Future of Single-Chain Antibody Fragments (scFvs)
StableBody Technologies LLC has developed an elegantly simple, yet incredibly powerful method to design, engineer, and
produce large numbers of structurally and functionally improved single-chain antibody fragments (scFvs).
This disruptive core technology can be directly applied to unmet protein engineering needs in many markets, including:
stabilized protein kits for clinical diagnostics which can be shipped/stored at ambient temperatures
more potent therapeutic proteins to improve treatment efficacy
reduce reagent costs
extension to existing patents
improved biothreat or environmental testing kits for defense applications
these scFv reagents are cold chain free